Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline and Incentives for E-cigarette Cessation in Adults Who Co-use Cannabis
NCT06688539Phase 4Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of varenicline in nicotine dependence and Tobacco Use Disorder (TUD), sponsored by Medical University of South Carolina. Primary endpoint: 7-day point prevalence tobacco abstinence at 12 weeks. Started Feb 2025; status: recruiting.
02
Drugs
varenicline
03
Conditions
nicotine dependenceTobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06688539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688539.